Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Regulation

Governor Christie Signs Oroho Bill to Remove Red Tape from Pharmaceutical Industry

Sen. Steve Oroho

Sen. Steve Oroho

Trenton, NJ, December 7, 2016 — Legislation sponsored by Senator Steve Oroho (R-Sussex, Warren, Morris) to ma

ke the registration process easier for pharmaceutical companies is now law after it was signed by Governor Chris Christie.

The measure came out of the New Jersey Red Tape Review Commission.

“The seemingly never ending list of regulations and rules has handcuffed business in this state for far too long,” Senator Oroho said. Continue reading

Lt. Governor Guadagno’s Red Tape Review Commission Tries to Ease Doing Business in NJ

Kim Guadagno high resTrenton, NJ, September 9, 2015 ― John Reitmeyer reports in NJ Spotlight that a recently signed measure is just the most recent to come out of the Red Tape Review Commission a panel that studies bureaucracy and conflicting regulations in state government and has been led by Lt. Governor Kim Guadagno for more than five years.

Though often overlooked, the bipartisan commission has inspired several measures like the recently signed nonprofit raffle bill that have rewritten state laws since it was created by executive order in 2010.  Other bills have changed state incorporation rules, modernized the issuing of liquor licenses, and eliminated executive branch boards and commissions. Continue reading

Event: NJ Civil Justice Institute to Host Fall Legal Reform Conference on September 18

Trenton, NJ, August 29, 2015 ― The New Jersey Civil Justice Institute will host a half day conference on September 18 to increase awareness of the hidden legal risk that is blindsiding New Jersey businesses – private lawsuits over regulatory violations.

The event, which is being held at the Hotel Woodbridge at Metropark from 8 a.m. to 1:30 p.m., will feature a networking breakfast, two panel discussions with lawmakers, including: Continue reading

Pharmalot: FDA Wants Consumer-Friendly Drug Ads

New York, NY, February 8, 2015 ― Pharmalot reports that anyone who leafs through a newspaper or magazine and sees prescription drug ads would be hard-pressed to miss the lengthy fine print describing risks and caveats in copious detail.  Drug makers include this information to comply with the law.

But after years of complaints and concerns this amounts to information overload to consumers, the Food and Drug Administration (FDA) is proposing a new approach.

In a new draft guidance, the FDA suggests that drug makers instead offer “consumer-friendly” summaries in print ads and promotional materials.   Continue reading

FDA Head Margaret Hamburg to Depart; Ostroff to Be Acting Chief

Washington, DC, February 5, 2015 The Washington Post reports that Dr. Margaret Hamburg, who as commissioner of the Food and Drug Administration (FDA) over the past six years has presided over new initiatives on food safety and tobacco regulation and has worked to fast-track new breakthrough drugs, plans to resign from her post at the end of March.

Stephen Ostroff, the FDA’s chief scientist and a former official at the Centers for Disease Control and Prevention, will take over in the top post until President Obama names a successor for Hamburg. Continue reading

FDA to Create New Drug Quality Office to Focus on Manufacturing

Washington, DC, January 13, 2015 The Wall Street Journal has reported that the Food and Drug Administration plans to create a new Office of Pharmaceutical Quality to focus in part on manufacturing problems such as those that have beset generic companies that make extended-release versions of drugs.

The agency said it isn’t creating the office because of quality concerns, but rather to make its focus on manufacturing more systematic.

Dr. Janet Woodcock, director of the FDA’s center for drugs, said the office is intended in part to create parity between brand-name and generic drugs. Continue reading

Rutgers to Host Pharmaceutical Regulatory Compliance Workshop September 26

Piscataway, NJ, September 17, 2013 — The NSF Center for Structured Organic Particulate Systems (C-SOPS) based at Rutgers University will host industry representatives at the inaugural meeting of the Rutgers’ Consortium on Regulatory Compliance Exploration and Services (CRCES), on Thursday September 26 at Rutgers, Busch Campus in Piscataway, NJ.

C-SOPS and representatives from biopharmaceutical companies will work together in this consortium to provide on-going support to pharma companies to maintain regulatory compliance in their manufacturing and R&D — despite an ever changing regulatory environment. Continue reading